Dipòsit Digital de Documents de la UAB
Publication
Artículo científico (JournalArticle)
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Background and Aims: Polycystic liver diseases (PLDs) are genetic disorders characterized by progressive development of symptomatic biliary cysts. Current surgical and pharmacological approaches are ineffective, and liver transplantation represents the only curative option. Ursodeoxycholic acid (UDCA) and histone deacetylase 6 inhibitors (HDAC6is) have arisen as promising therapeutic strategies, but with partial benefits. Approach and Results: Here, we tested an approach based on the design, synthesis, and validation of a family of UDCA synthetic conjugates with selective HDAC6i capacity (UDCA-HDAC6i). Four UDCA-HDAC6i conjugates presented selective HDAC6i activity, UDCA-HDAC6i #1 being the most promising candidate. UDCA orientation within the UDCA-HDAC6i structure was determinant for HDAC6i activity and selectivity. Treatment of polycystic rats with UDCA-HDAC6i #1 reduced their hepatomegaly and cystogenesis, increased UDCA concentration, and inhibited HDAC6 activity in liver. In cystic cholangiocytes UDCA-HDAC6i #1 restored primary cilium length and exhibited potent antiproliferative activity. UDCA-HDAC6i #1 was actively transported into cells through BA and organic cation transporters. Conclusions: These UDCA-HDAC6i conjugates open a therapeutic avenue for PLDs.
Project:
Instituto de Salud Carlos III PI15-01132
,
Instituto de Salud Carlos III PI18-01075
,
Instituto de Salud Carlos III CON14-00129
,
Instituto de Salud Carlos III PI14-00399
,
Instituto de Salud Carlos III PI17-00022
,
Instituto de Salud Carlos III PI16-00598
,
Ministerio de Economía y Competitividad RYC-2015-17755
,
Ministerio de Economía y Competitividad BES-2014-069148
,
Ministerio de Ciencia e Innovación CTQ2016-80375-P
,
Ministerio de Economía y Competitividad CTQ2014-51912-REDC